Anthropic Opens Biology Wet Lab to Automate Drug Discovery

AI startup Anthropic has established a biological wet lab in the San Francisco Bay Area to advance its ambitions in drug science and preclinical research. The company is training its Claude AI model to direct robotic units to automate laboratory experiments, specifically targeting rare diseases and conditions previously considered undruggable that the pharmaceutical industry often neglects.

To support this initiative, Anthropic acquired the startup Coefficient Bio and added Novartis CEO Vasant Narasimhan to its board of directors. While the company provides AI tools and the Model Hardware Standard to partners such as Novo Nordisk, Bristol Myers Squibb, and Roche's Genentech, it is not currently running clinical trials to avoid direct competition with biotech firms.

This expansion into physical biology occurs alongside internal warnings regarding the existential risks of artificial intelligence. CEO Dario Amodei has claimed AI could cure most major diseases within five to 10 years, yet he has simultaneously called for a research slowdown to prevent catastrophic damage and bioterrorism risks. Other leadership and former staff have been more dire; alignment lead Evan Hubinger estimated a greater than 10% probability that AI could wipe out humanity within a decade, a sentiment echoed by former researcher Jacob Coxon.